Calix Valuation
Is CXL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CXL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CXL's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CXL's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CXL?
Key metric: As CXL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is CXL's PS Ratio? | |
|---|---|
| PS Ratio | 6x |
| Sales | AU$24.19m |
| Market Cap | AU$146.67m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.4x |
| Enterprise Value/EBITDA | -3.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CXL's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.4x | ||
SDV SciDev | 0.9x | 10.0% | AU$95.9m |
CG1 Carbonxt Group | 1.3x | n/a | AU$19.3m |
MCO Myeco Group | 1.5x | n/a | AU$22.7m |
RAN Range International | 1.9x | n/a | AU$5.6m |
CXL Calix | 6x | 28.4% | AU$146.7m |
Price-To-Sales vs Peers: CXL is expensive based on its Price-To-Sales Ratio (6x) compared to the peer average (1.2x).
Price to Sales Ratio vs Industry
How does CXL's PS Ratio compare vs other companies in the AU Chemicals Industry?
Price-To-Sales vs Industry: CXL is expensive based on its Price-To-Sales Ratio (6x) compared to the Australian Chemicals industry average (4.8x).
Price to Sales Ratio vs Fair Ratio
What is CXL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 6x |
| Fair PS Ratio | 3.2x |
Price-To-Sales vs Fair Ratio: CXL is expensive based on its Price-To-Sales Ratio (6x) compared to the estimated Fair Price-To-Sales Ratio (3.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | AU$0.80 | AU$1.98 +147.9% | 17.5% | AU$2.40 | AU$1.55 | n/a | 3 |
| Nov ’25 | AU$0.89 | AU$1.98 +122.8% | 17.5% | AU$2.40 | AU$1.55 | n/a | 3 |
| Oct ’25 | AU$1.18 | AU$2.43 +106.2% | 18.5% | AU$3.00 | AU$1.90 | n/a | 3 |
| Sep ’25 | AU$0.96 | AU$2.43 +153.5% | 18.5% | AU$3.00 | AU$1.90 | n/a | 3 |
| Aug ’25 | AU$0.95 | AU$3.45 +261.3% | 30.4% | AU$4.50 | AU$2.40 | n/a | 2 |
| Jul ’25 | AU$1.46 | AU$3.45 +136.3% | 30.4% | AU$4.50 | AU$2.40 | n/a | 2 |
| Jun ’25 | AU$1.38 | AU$4.80 +247.8% | 6.3% | AU$5.10 | AU$4.50 | n/a | 2 |
| May ’25 | AU$1.42 | AU$5.77 +306.1% | 24.1% | AU$7.70 | AU$4.50 | n/a | 3 |
| Apr ’25 | AU$1.47 | AU$5.77 +293.6% | 24.1% | AU$7.70 | AU$4.50 | n/a | 3 |
| Mar ’25 | AU$1.78 | AU$5.77 +224.0% | 24.1% | AU$7.70 | AU$4.50 | n/a | 3 |
| Feb ’25 | AU$1.70 | AU$6.27 +268.6% | 17.2% | AU$7.70 | AU$5.10 | n/a | 3 |
| Jan ’25 | AU$3.43 | AU$6.98 +103.6% | 10.3% | AU$7.70 | AU$6.00 | n/a | 3 |
| Dec ’24 | AU$3.47 | AU$6.98 +101.2% | 10.3% | AU$7.70 | AU$6.00 | n/a | 3 |
| Nov ’24 | AU$2.82 | AU$6.98 +147.6% | 10.3% | AU$7.70 | AU$6.00 | AU$0.89 | 3 |
| Oct ’24 | AU$2.82 | AU$8.27 +193.1% | 22.2% | AU$10.50 | AU$6.00 | AU$1.18 | 3 |
| Sep ’24 | AU$3.87 | AU$8.27 +113.6% | 22.2% | AU$10.50 | AU$6.00 | AU$0.96 | 3 |
| Aug ’24 | AU$4.13 | AU$8.50 +105.8% | 22.0% | AU$10.50 | AU$6.00 | AU$0.95 | 3 |
| Jul ’24 | AU$4.17 | AU$8.50 +103.8% | 22.0% | AU$10.50 | AU$6.00 | AU$1.46 | 3 |
| Jun ’24 | AU$4.16 | AU$8.50 +104.3% | 22.0% | AU$10.50 | AU$6.00 | AU$1.38 | 3 |
| May ’24 | AU$4.74 | AU$8.50 +79.3% | 22.0% | AU$10.50 | AU$6.00 | AU$1.42 | 3 |
| Apr ’24 | AU$4.74 | AU$8.50 +79.3% | 22.0% | AU$10.50 | AU$6.00 | AU$1.47 | 3 |
| Mar ’24 | AU$5.60 | AU$8.50 +51.8% | 22.0% | AU$10.50 | AU$6.00 | AU$1.78 | 3 |
| Feb ’24 | AU$5.44 | AU$8.50 +56.2% | 22.0% | AU$10.50 | AU$6.00 | AU$1.70 | 3 |
| Jan ’24 | AU$4.47 | AU$8.25 +84.6% | 27.3% | AU$10.50 | AU$6.00 | AU$3.43 | 2 |
| Dec ’23 | AU$5.15 | AU$8.25 +60.2% | 27.3% | AU$10.50 | AU$6.00 | AU$3.47 | 2 |
| Nov ’23 | AU$4.30 | AU$8.00 +86.0% | 25.0% | AU$10.00 | AU$6.00 | AU$2.82 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Incitec Pivot
AU$5.9b
Manufactures and distributes industrial explosives, industrial chemicals, and fertilizers in Australia and the United State.
IPL
AU$3.15
7D
4.8%
1Y
10.2%
Capral
AU$160.0m
Manufactures, markets, and distributes fabricated and semi-fabricated aluminum related products in Australia.
CAA
AU$9.19
7D
-2.9%
1Y
5.1%
Nufarm
AU$1.6b
Develops, manufactures, and sells crop protection solutions and seed technologies in Europe, the Middle East, Africa, North America, and the Asia Pacific.
NUF
AU$4.07
7D
4.9%
1Y
-11.5%